Newman, KL, Leon, JS. Norovirus immunology: of mice and mechanisms. European Journal of Immunology
2015; 45: 2742–2757.
Bavishi, C, Dupont, HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics
2011; 34: 1269–1281.
Lambert, AA, et al.
Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. Published online: 4 June 2015. doi: 10.1371/journal.pone.0128004.
Coniglio, N, et al.
The effect of proton pump inhibitors in increasing the risk of developing travellers’ diarrhoea – a literature review. Australian Pharmacist
2012; 31: 416–419.
Parkman, HP, et al.
Effect of gastric acid suppressants on human gastric motility. Gut
1998; 42: 243–250.
Sanaka, M, Yamamoto, T, Kuyama, Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Digestive Diseases and Sciences
2010; 55: 2431–2440.
Wandall, JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut
1992; 33: 617–621.
De Jonge, PJF, et al.
Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Alimentary Pharmacology & Therapeutics
2008; 28: 127–136.
Ettayebi, K, et al.
Replication of human noroviruses in stem cell-derived human enteroids. Science
2016; 353: 1387–1393.
Cannon, JL, et al.
Surrogates for the study of norovirus stability and inactivation in the environment: a comparison of murine norovirus and feline calicivirus. Journal of Food Protection
2006; 69: 2761–2765.
Weston, D. Infection Prevention and Control: Theory and Clinical Practice for Healthcare Professionals. West Sussex: John Wiley & Sons Ltd, 2008, pp. 189–201.
Deshpande, A, et al.
Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association
2012; 10: 225–233.
Pearce, N. What does the odds ratio estimate in a case-control study?
International Journal of Epidemiology
1993; 22: 1189–1192.
Jones, MK, et al.
Enteric bacteria promote human and mouse norovirus infection of B cells. Science
2014; 346: 755–759.
Karst, SM, Zhu, S, Goodfellow, IG. The molecular pathology of noroviruses. The Journal of Pathology
2015; 235: 206–216.
Kwok, CS, Yeong, JK-Y, Loke, YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone
2011; 48: 768–776.
Jena, AB, Sun, E, Goldman, DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. Journal of General Internal Medicine
2013; 28: 223–230.
Vashist, S, et al.
Model systems for the study of human norovirus Biology. Future Virology
2009; 4: 353–367.
Heidelbaugh, JJ, Goldberg, KL, Inadomi, JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. The American Journal of Managed Care
2010; 16: e228–234.
Akram, F, et al.
Proton pump inhibitors: are we still prescribing them without valid indications?
The Australasian Medical Journal
2014; 7: 465–470.
Ksiadzyna, D, Szelag, A, Paradowski, L. Overuse of proton pump inhibitors. Polskie Archiwum Medycyny Wewnetrznej
2015; 125: 289–298.